Format

Send to

Choose Destination
See comment in PubMed Commons below
Pathology. 2001 Nov;33(4):425-7.

HER2 testing recommendations in Australia.

Author information

1
Tissue Pathology Department, ICPMR, Westmead Hospital, NSW, Australia. michaelb@icpmr.wsahs.nsw.gov.au

Abstract

HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.

PMID:
11827407
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center